BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

157 related articles for article (PubMed ID: 34897468)

  • 1. Characterization of Subtypes of BRAF-Mutant Papillary Thyroid Cancer Defined by Their Thyroid Differentiation Score.
    Boucai L; Seshan V; Williams M; Knauf JA; Saqcena M; Ghossein RA; Fagin JA
    J Clin Endocrinol Metab; 2022 Mar; 107(4):1030-1039. PubMed ID: 34897468
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Co-inhibition of SMAD and MAPK signaling enhances 124I uptake in BRAF-mutant thyroid cancers.
    Luckett KA; Cracchiolo JR; Krishnamoorthy GP; Leandro-Garcia LJ; Nagarajah J; Saqcena M; Lester R; Im SY; Zhao Z; Lowe SW; de Stanchina E; Sherman EJ; Ho AL; Leach SD; Knauf JA; Fagin JA
    Endocr Relat Cancer; 2021 May; 28(6):391-402. PubMed ID: 33890869
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Noninferior response in BRAF(V600E) mutant nonmetastatic papillary thyroid carcinoma to radioiodine therapy.
    Li J; Liang J; Zhao T; Lin Y
    Eur J Nucl Med Mol Imaging; 2016 Jun; 43(6):1034-9. PubMed ID: 26780618
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The molecular and gene/miRNA expression profiles of radioiodine resistant papillary thyroid cancer.
    Colombo C; Minna E; Gargiuli C; Muzza M; Dugo M; De Cecco L; Pogliaghi G; Tosi D; Bulfamante G; Greco A; Fugazzola L; Borrello MG
    J Exp Clin Cancer Res; 2020 Nov; 39(1):245. PubMed ID: 33198784
    [TBL] [Abstract][Full Text] [Related]  

  • 5.
    Pekova B; Sykorova V; Dvorakova S; Vaclavikova E; Moravcova J; Katra R; Astl J; Vlcek P; Kodetova D; Vcelak J; Bendlova B
    Thyroid; 2020 Dec; 30(12):1771-1780. PubMed ID: 32495721
    [No Abstract]   [Full Text] [Related]  

  • 6. Molecular characterization of tumors meeting diagnostic criteria for the non-invasive follicular thyroid neoplasm with papillary-like nuclear features (NIFTP).
    Pool C; Walter V; Bann D; Goldenberg D; Broach J; Hennessy M; Cottrill E; Washburn E; Williams N; Crist H; Imamura Y; Warrick JI
    Virchows Arch; 2019 Mar; 474(3):341-351. PubMed ID: 30645670
    [TBL] [Abstract][Full Text] [Related]  

  • 7. BRAF
    Shi C; Cao J; Shi T; Liang M; Ding C; Lv Y; Zhang W; Li C; Gao W; Wu G; Man J
    World J Surg Oncol; 2020 Jun; 18(1):145. PubMed ID: 32593310
    [TBL] [Abstract][Full Text] [Related]  

  • 8. A Shift in Molecular Drivers of Papillary Thyroid Carcinoma Following the 2017 World Health Organization Classification: Characterization of 554 Consecutive Tumors With Emphasis on BRAF-Negative Cases.
    Hang JF; Chen JY; Kuo PC; Lai HF; Lee TL; Tai SK; Kuo CS; Chen HS; Li WS; Li CF
    Mod Pathol; 2023 Sep; 36(9):100242. PubMed ID: 37307878
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Different Molecular Phenotypes of Progression in BRAF- and RAS-Like Papillary Thyroid Carcinoma.
    Lim J; Lee HS; Park J; Kim KS; Kim SK; Cho YW; Song YS
    Endocrinol Metab (Seoul); 2023 Aug; 38(4):445-454. PubMed ID: 37461149
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Characterization of TERT and BRAF copy number variation in papillary thyroid carcinoma: An analysis of the cancer genome atlas study.
    McKelvey BA; Zeiger MA; Umbricht CB
    Genes Chromosomes Cancer; 2021 Jun; 60(6):403-409. PubMed ID: 33305870
    [TBL] [Abstract][Full Text] [Related]  

  • 11. BRAF mutation associated with other genetic events identifies a subset of aggressive papillary thyroid carcinoma.
    Costa AM; Herrero A; Fresno MF; Heymann J; Alvarez JA; Cameselle-Teijeiro J; García-Rostán G
    Clin Endocrinol (Oxf); 2008 Apr; 68(4):618-34. PubMed ID: 18070147
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Association between diffuse lymphocytic infiltration and papillary thyroid cancer aggressiveness according to the presence of thyroid peroxidase antibody and BRAF
    Lee YK; Park KH; Park SH; Kim KJ; Shin DY; Nam KH; Chung WY; Lee EJ
    Head Neck; 2018 Oct; 40(10):2271-2279. PubMed ID: 29935011
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Association of BRAF V600E Mutation and MicroRNA Expression with Central Lymph Node Metastases in Papillary Thyroid Cancer: A Prospective Study from Four Endocrine Surgery Centers.
    Han PA; Kim HS; Cho S; Fazeli R; Najafian A; Khawaja H; McAlexander M; Dy B; Sorensen M; Aronova A; Sebo TJ; Giordano TJ; Fahey TJ; Thompson GB; Gauger PG; Somervell H; Bishop JA; Eshleman JR; Schneider EB; Witwer KW; Umbricht CB; Zeiger MA
    Thyroid; 2016 Apr; 26(4):532-42. PubMed ID: 26950846
    [TBL] [Abstract][Full Text] [Related]  

  • 14. TGF-beta/Smad pathway and BRAF mutation play different roles in circumscribed and infiltrative papillary thyroid carcinoma.
    Eloy C; Santos J; Cameselle-Teijeiro J; Soares P; Sobrinho-Simões M
    Virchows Arch; 2012 Jun; 460(6):587-600. PubMed ID: 22527019
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Vemurafenib Redifferentiation of BRAF Mutant, RAI-Refractory Thyroid Cancers.
    Dunn LA; Sherman EJ; Baxi SS; Tchekmedyian V; Grewal RK; Larson SM; Pentlow KS; Haque S; Tuttle RM; Sabra MM; Fish S; Boucai L; Walters J; Ghossein RA; Seshan VE; Ni A; Li D; Knauf JA; Pfister DG; Fagin JA; Ho AL
    J Clin Endocrinol Metab; 2019 May; 104(5):1417-1428. PubMed ID: 30256977
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Detection of RET rearrangements in papillary thyroid carcinoma using RT-PCR and FISH techniques - A molecular and clinical analysis.
    Musholt TJ; Staubitz JI; Antonio Cámara RJ; Musholt PB; Humberg D; Springer E; Schad A
    Eur J Surg Oncol; 2019 Jun; 45(6):1018-1024. PubMed ID: 30472213
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Interaction of BRAF-induced ETS factors with mutant TERT promoter in papillary thyroid cancer.
    Song YS; Yoo SK; Kim HH; Jung G; Oh AR; Cha JY; Kim SJ; Cho SW; Lee KE; Seo JS; Park YJ
    Endocr Relat Cancer; 2019 Jun; 26(6):629-641. PubMed ID: 30999281
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Association of Polygenic Score With Tumor Molecular Subtypes in Papillary Thyroid Carcinoma.
    Wang JR; Zafereo ME; Wang W; Joshu C; Ray D
    J Clin Endocrinol Metab; 2023 Dec; 109(1):e306-e313. PubMed ID: 37453101
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Overexpression of miR-221 is associated with aggressive clinicopathologic characteristics and the BRAF mutation in papillary thyroid carcinomas.
    Zhou YL; Liu C; Dai XX; Zhang XH; Wang OC
    Med Oncol; 2012 Dec; 29(5):3360-6. PubMed ID: 22855362
    [TBL] [Abstract][Full Text] [Related]  

  • 20. BRAF V600E mutation and microRNAs are helpful in distinguishing papillary thyroid malignant lesions: Tissues and fine needle aspiration cytology cases.
    Zarkesh M; Zadeh-Vakili A; Akbarzadeh M; Nozhat Z; Fanaei SA; Hedayati M; Azizi F
    Life Sci; 2019 Apr; 223():166-173. PubMed ID: 30890403
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.